MARKET

NMTR

NMTR

9 Meters Biopharma Inc
NASDAQ
2.310
-0.020
-0.86%
After Hours: 2.340 +0.03 +1.30% 17:59 02/03 EST
OPEN
2.290
PREV CLOSE
2.330
HIGH
2.370
LOW
2.230
VOLUME
90.71K
TURNOVER
0
52 WEEK HIGH
14.89
52 WEEK LOW
1.000
MARKET CAP
29.93M
P/E (TTM)
-0.7208
1D
5D
1M
3M
1Y
5Y
BRIEF-9 Meters Biopharma Says On January 12, Co And Holder Agreed To Amend The A&R Note
Reuters · 01/13 14:21
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga · 01/05 18:01
NMTR and SLRX among healthcare movers
Seeking Alpha · 01/05 15:30
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
Benzinga · 12/30/2022 17:28
BRIEF-9 Meters Biopharma Inc - 9 Meters Biopharma Announces Phase 3 Study Of Vurolenatide In Short Bowel Syndrome
Reuters · 11/29/2022 13:24
9 Meters Biopharma Finalizes Design of Phase 3 Clinical Trial of Proposed Treatment for Short Bowel Syndrome
9 Meters Biopharma Finalizes Design of Phase 3 Clinical Trial of Proposed Treatment for Short Bowel Syndrome
MT Newswires · 11/29/2022 12:19
9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration With Gustave Roussy
Benzinga · 11/14/2022 13:04
BMO Capital Maintains Outperform on 9 Meters Biopharma, Lowers Price Target to $35
Benzinga · 11/10/2022 14:42
More
About NMTR
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs. Its pipeline includes Vurolenatide, Larazotide, NM-102, NM-003, NM-136 and NM-004. Vurolenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that combines exenatide with an extended half-life technology for treatment of short bowel syndrome (SBS). Larazotide is an 8-amino acid peptide formulated into an orally administered capsule for treatment of celiac disease. NM-102 is a small molecule peptide, is being developed as a potential microbiome modulator and is undergoing an indication selection process. NM-003 is a long-acting GLP-2 receptor agonist, for prevention of acute graft versus host disease. NM-004 is a double-cleaved mesalamine with an immunomodulator for pediatric ulcerative colitis.

Webull offers kinds of 9 Meters Biopharma Inc stock information, including NASDAQ:NMTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NMTR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NMTR stock methods without spending real money on the virtual paper trading platform.